Clinical trials: Hepatobiliary Cancer
Solid Tumor
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR…
- Trial name
- NCT01752920
- Testing
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range
- Where
- 12 sites in United States, Italy
- Volunteers
- 119 people
- Sponsor
- Basilea Pharmaceutica
Liver Neoplasms, Neoplasm Metastases
Stereotactic Radiotherapy (SRT) Liver (COLD 1)
A minority of patients with colorectal liver metastases and hepatobiliary cancer (primary liver cancer) are candidates for surgery, but there are no curative treatment options for these patients.
- Trial name
- NCT00152906
- Testing
- Stereotactic radiotherapy (SRT) or highly conformal (CRT)
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- University Health Network, Toronto